Evidence-Based Reviews

ADHD and substance abuse: 4 therapeutic options for patients with addictions

Current Psychiatry. 2002 November;1(11):58-68

References

1. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-76.

2. Sullivan MA, Rudnik-Levin F. Attention deficit/hyperactivity disorder and substance abuse. Diagnostic and therapeutic considerations. Ann NY Acad Sci 2001;931:251-70.

3. Hunt RD. Nosology, neurobiology, and clinical patterns of ADHD in adults. Psychiatric Ann 1997;27:572-81.

4. Taylor MA. Evaluation and management of attention-deficit hyperactivity disorder. Am Fam Phys 1997;55:887-904.

5. Diller LH. The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Hasting Center Report 1996;26:12-18.

6. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotrophic medications: primary care, psychiatry, and other medical specialties. JAMA 1998;279:526-31.

7. Mortan WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. J Clin Psychiatry (Primary Care) 2000;2:159-64.

8. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456-63.

9. Banov MD, Palmer T, Brody E. Antidepressants are as effective as stimulants in the long-term treatment of ADHD in Adults. Primary Psychiatry 2001;8:54-7.

10. Moline S, Frankenberger W. Use of stimulant medication for treatment of attention-deficit/hyperactivity disorder. A survey of middle and high school students attitudes. Psychology in the Schools 2001;38:569-84.

11. Prescription drugs: abuse and addiction. National Institute on Drug Abuse Research Report Series. NIH publication number 01-4881, July 2001.

12. Mann A. Illicit methylphenidate trade appears widespread. Clinical Psychiatry News June 2000;28(6):5-

13. ABCNews.com. http://more/abcnews.go.com/sections/living/DailyNews/ritalin0505.html

14. Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract 1999;48:15-20.

15. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha2-noradrenergic mechanisms to prefrontal cortical cognitive function. Arch Gen Psychiatry 1996;53:448-55.

16. DuPaul G. The ADHD Rating Scale: normative data, reliability, and validity. Worcester, MA: University of Massachusetts Medical School, 1990.

17. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention-deficit/hyperactivity disorder. Am J Psychiatry 1996;153:1147-53.

18. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43.

19. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention-deficit/hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-8.

20. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention-deficit/hyperactivity disorder in adults. Ann Clin Psychiatry 2001;13:129-34.

21. Wooltorton E. Bupropion (Zyban, Wellbutrin SR): reports of death, seizures, serum sickness. Can Med J 2002;166:68.-

22. Upadhyaya HP, Brady KT, Sethuraman G, et al. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol 2001;21:116-8.

23. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.

24. Spencer T, Biederman J, Wilens T, Prince J, Hatch M. Effectiveness and tolerability of tomoxetine in adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 1998;155:693-5.

25. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83.-

26. Kratochvil C, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in ADHD children: a randomized, open-label trial (presentation). Honolulu: American Academy of Child and Adolescent Psychiatry, October, 2001.

Though no head-to-head studies have compared desipramine with methylphenidate, the same researchers conducted a similar placebo-controlled study with methylphenidate. The 6-week symptom score on the ADHD Rating Scale was 12.5 for methylphenidate, compared with a score of 12 for desipramine.¹⁸

Recommendation. Desipramine may be the most effective of the antidepressant treatments for patients with ADHD. Because of its side effects, however, it is not this author’s first choice and is usually reserved for patients whose symptoms fail to respond to other antidepressants. Desipramine can cause sedation, dry mouth, and constipation, which are related to blockade of adrenergic, histamine, and muscarinic cholinergic receptors. It also can be lethal in overdose.

Some substance abusers lose confidence in a medication that they cannot feel working. The side effects of desipramine, which can be intolerable for some patients, can reassure others with a history of substance abuse that they are being medicated.

Bupropion

Bupropion is a unique antidepressant that inhibits the presynaptic reuptake of dopamine and norepinephrine. Open-label studies demonstrate good responses to bupropion by adults with ADHD. One placebo-controlled, double-blind study found improved ADHD symptoms in 76% of patients receiving bupropion SR, compared with 37% of those receiving a placebo; the difference was statistically significant.¹⁹

Figure 2 IMPROVED ADHD SYMPTOMS WITH DESIPRAMINE

Adults with ADHD who received desipramine, 200 mg/d, in a double-blind trial showed significantly less hyperactivity, impulsivity, and inattentiveness after 6 weeks of therapy than a control group that received a placebo.

Source: Adapted with permission from Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention-deficit/hyperactivity disorder. Am J Psychiatry 1996;153:1147-53.Another study of adults with ADHD compared bupropion SR to methylphenidate and a placebo.²⁰ Using a primary outcome of the Clinical Global Impression (CGI) scale, response rates were 64% for bupropion SR, 50% for methylphenidate, and 27% for the placebo. The difference in response rates between the two agents was not statistically significant (p = 0.14).

Recommendation. The risk of seizures with bupropion is about 1 in 1,000. Therefore, bupropion should not be given to patients with a seizure disorder or to those with conditions that alter the seizure threshold (e.g., eating disorders, recent head trauma, or benzodiazepine withdrawal).²¹

This author uses bupropion as first-line treatment for appropriate patients with ADHD and a substance abuse history. Bupropion’s mild benefit with smoking cessation may provide some crossover effect for other substances of abuse. The low incidence of sexual side effects is another benefit. Drawbacks include twice-daily dosing and lack of a robust effect on attention and concentration.

Venlafaxine

Venlafaxine is a potent inhibitor of serotonin reuptake, a moderate inhibitor of norepinephrine, and a mild inhibitor of dopamine. Venlafaxine has displayed response rates similar to those of desipramine and bupropion in open-label studies in adults with ADHD,¹⁴ but no placebo-controlled studies exist.

As noted above, these antidepressants are believed to improve ADHD symptoms by making norepinephrine more available at the synapse. Hypothetically, then, one would need to administer venlafaxine at dosages that adequately inhibit the norepinephrine reuptake receptor. Venlafaxine XR, 150 mg/d, provides significant norepinephrine activity, according to several lines of evidence.

Recently, Upadhyaya et al reported the use of venlafaxine in one of the few treatment studies of patients with ADHD and comorbid alcohol/cocaine abuse. In an open-label trial, 10 subjects received venlafaxine, up to 300 mg/d, along with psychotherapy and attendance at Alcoholics Anonymous meetings. The nine who completed 4 weeks of treatment showed significantly improved ADHD symptoms and decreased alcohol craving.²²

Recommendation. Venlafaxine is this author’s second choice for patients with ADHD and substance abuse problems. Sexual side effects that some patients experience with venlafaxine can limit its use. Some clinicians are concerned about increases in blood pressure associated with venlafaxine, although significant changes do not seem to occur at dosages below 300 mg/d.²³

Atomoxetine

Atomoxetine is an investigational antidepressant in phase-III trials as a treatment for ADHD. Evidence shows atomoxetine to be a potent inhibitor of the presynaptic norepinephrine transporter, with minimal affinity for other neurotransmitter receptors. Initial studies suggest that atomoxetine is effective for adults and children with ADHD:

In a small, double-blind, placebo-controlled, crossover trial, 11 of 20 adults showed improvement in ADHD symptoms within 3 weeks of starting atomoxetine.²⁴
In 297 children and adolescents, atomoxetine at dosages averaging approximately 1.2 mg/kg/d was more effective than a placebo in reducing ADHD symptoms and improving social and family functioning. Treatment was well tolerated and without significant side effects.²⁵
In a randomized open-label trial, 228 children received atomoxetine or methylphenidate. Both treatments significantly reduced inattention and hyperactive/impulsive symptoms.²⁶